Petosemtamab + Pembrolizumab vs. Pembrolizumab in 1st line treatment of PD-L1+ Head & Neck squamous cell carcinoma

A phase III randomized, open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Disease Types: Head and Neck

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A phase III randomized, open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

For More Information:

https://clinicaltrials.gov/study/NCT06525220?term=MCLA-158-CL03&rank=1